Alzheimer’s registry for people with memory concerns or risk
Part of Brain & nervous system, Mental health clinical trials.
This is a research registry that helps doctors compare how different memory and Alzheimer’s risk groups change over time. It may help researchers learn which people are more likely to develop Alzheimer’s and how to better track early changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have a family history of Alzheimer’s disease
- Have no memory complaints, or have early memory changes such as subjective cognitive decline
- Or be identified as having preclinical Alzheimer’s, or mild cognitive impairment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information from people with mild cognitive impairment or Alzheimer's disease who are starting a new medication. It helps researchers learn more about these conditions and their treatments over time.
This study creates a registry for people who are using newly approved Alzheimer's medications. It tracks how these treatments work over time and may help researchers learn more about diagnosing and treating Alzheimer's.
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.